PSTV Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Plus Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerPSTV

Market Cap41.1M

Cash RunwayRunway 6-12 months

Next Catalyst2030-04-01

Public Research Snapshot

Plus Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Pirtobrutinib in Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Microspheres	precisely targeting tumors, as well as gamma rays for live imaging throughout treatment	n/a	n/a	Public pipeline row
RNL-186	n/a	n/a	Phase 1	Public pipeline row
July 24, 2025	n/a	n/a	n/a	Public pipeline row
Rhenium-188	n/a	Small Molecule	n/a	Public pipeline row
REYOBIQ™ (rhenium Re186 obisbemeda)	n/a	n/a	n/a	Public pipeline row
2. Services	n/a	n/a	Registrational	Public pipeline row
3. Registration, Password	n/a	n/a	Registrational	Public pipeline row
Pirtobrutinib	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma	n/a	Phase 3	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2030-04-01	GDC-0587	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01135680	Phase 1	COMPLETED	98	2010-09
NCT04552379	Phase 3	COMPLETED	1173	2021-05-31
NCT05060003	Phase 2	TERMINATED	7	2023-11-27
NCT05023980	Phase 3	ACTIVE_NOT_RECRUITING	309	2025-07-11
NCT07214662	Phase 1	RECRUITING	136	2030-04-01

Scientific Context

asset_name | 2. Services
clinical_stage | Registrational
asset_name | 3. Registration, Password
clinical_stage | Registrational
asset_name | Atezolizumab

Want the full PSTV research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.